PriceTargets.com logo

BlossomHill Therapeutics - BLSM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.00
  • Forecasted Upside: 55.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$20.00 As of 09/1/2026 09:56 AM ET
▲ +1.7 (9.29%)

This chart shows the closing price for BLSM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BlossomHill Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLSM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLSM

Analyst Price Target is $31.00
▲ +55.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BlossomHill Therapeutics in the last 3 months. The average price target is $31.00, with a high forecast of $35.00 and a low forecast of $28.00. The average price target represents a 55.00% upside from the last price of $20.00.

This chart shows the closing price for BLSM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in BlossomHill Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/1/2026GuggenheimInitiated CoverageBuy$30.00
9/1/2026HC WainwrightInitiated CoverageBuy$35.00
9/1/2026JPMorgan Chase & Co.Initiated CoverageOverweight$28.00
(Data available from 9/1/2021 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2026

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

BlossomHill Therapeutics logo
BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $20.00
Low: $20.00
High: $20.00

50 Day Range

MA: N/A

52 Week Range

Now: $20.00
Low: $15.25
High: $20.61

Volume

1,060 shs

Average Volume

218,174 shs

Market Capitalization

$612.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BlossomHill Therapeutics?

The following sell-side analysts have issued research reports on BlossomHill Therapeutics in the last year: Guggenheim, HC Wainwright, JPMorgan Chase & Co., and Wall Street Zen.
View the latest analyst ratings for BLSM.

What is the current price target for BlossomHill Therapeutics?

0 Wall Street analysts have set twelve-month price targets for BlossomHill Therapeutics in the last year. Their average twelve-month price target is $31.00, suggesting a possible upside of 69.4%. HC Wainwright has the highest price target set, predicting BLSM will reach $35.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $28.00 for BlossomHill Therapeutics in the next year.
View the latest price targets for BLSM.

What is the current consensus analyst rating for BlossomHill Therapeutics?

BlossomHill Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLSM will outperform the market and that investors should add to their positions of BlossomHill Therapeutics.
View the latest ratings for BLSM.